Headlands Research

Home
Headlands Research

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Headlands Research, Healthcare administrator, .

14/11/2025

Today on World Diabetes Day, we join the global call to create healthier, more supportive workplaces for people living with diabetes. This year’s theme, “Diabetes and the Workplace,” highlights that with proper care and support, everyone with diabetes can live and work well.

At Headlands Research, we’re proud to advance clinical studies that help improve the lives of those affected by diabetes, because access to better care begins with research.

13/11/2025

The Headlands Research team had a fantastic time connecting, learning, and sharing insights at ObesityWeek 2025! We’re grateful for the opportunity to engage in meaningful conversations about advancing obesity research and improving patient outcomes.

Pictured here:

• David Halpert, MD, Principal Investigator at JEM Research Institute
• Jason Agran, MD, PhD, Principal Investigator at Clinical Research Atlanta
• Ryan Cady, Director of Cardiometabolic and Pain Strategy, Headlands Research
• McKenzie Lang, Director of Business Development, Headlands Research
• Belinda Russell, Director of Recruitment Strategy, Headlands Research

It’s always inspiring to connect with others dedicated to improving the future of metabolic health.

12/11/2025

Dr. Beal Essink, Principal Investigator at Summit Research, a Headlands Research site, contributed to the landmark SURMOUNT-1 trial, now reporting 3-year outcomes in The New England Journal of Medicine.

This 3-year study found that adults with obesity and prediabetes who were treated with tirzepatide experienced sustained weight reductions of up to 19.7%, and markedly lower risk of developing type 2 diabetes (1.3% vs. 13.3% with placebo).

These findings reinforce tirzepatide’s potential to not only support meaningful, long-term weight loss but also to significantly delay or prevent the onset of type 2 diabetes.

Read more: https://headlandsresearch.com/news/tirzepatide-for-obesity-treatment-and-diabetes-prevention/

10/11/2025

We’re proud to highlight Dr. Lawrence Sher, Associate Medical Director at Peninsula Research Associates (PRA), a Headlands Research site located in Rolling Hills Estates, California.

Dr. Sher completed his medical degree at the University of Utah School of Medicine and his residency in pediatrics and fellowship in allergy and immunology at the University of California, Los Angeles.

Dr. Sher has served as Principal Investigator for more than 200 clinical trials in therapeutic areas such as asthma, COPD, allergic rhinitis, hypertension, ADHD, and sinusitis—contributing to the development of numerous approved medications and devices.

We’re honored to have Dr. Sher as part of the Headlands Research network and grateful for his ongoing contributions to advancing medical science and improving patient lives.

06/11/2025

Dr. Lawrence Sher, Associate Medical Director at Peninsula Research Associates, a Headlands Research site, co-authored a phase 3 study evaluating the long-term safety of epicutaneous immunotherapy (EPIT) with the VIASKIN peanut patch in children with peanut allergy. The findings were published in The Journal of Allergy and Clinical Immunology.

Results from the open-label extension of the REALISE trial showed that EPIT was well tolerated over 36 months, with high treatment adherence and decreasing frequency and severity of skin reactions over time.

Read more: https://headlandsresearch.com/news/long-term-safety-of-epicutaneous-immunotherapy-in-peanut-allergic-children/

03/11/2025

Today, we join communities worldwide in Light the World in Teal, part of Alzheimer’s Awareness Month from the Alzheimer's Foundation of America. Landmarks and homes will “go teal” to honor the millions of people living with Alzheimer’s and to show support for their families and caregivers.

At Headlands Research, we are committed to advancing clinical research that brings hope and progress for those affected. Together, we can shine a light on Alzheimer’s!

30/10/2025

Our experts will be at , and we hope to see you there! Schedule a time to chat during the show to learn how our Endocrine/Metabolic Program offers coordinated support across our site network.

https://headlandsresearch.com/events/obesityweek-2025/

29/10/2025

We’re proud to share that Christopher Romero, MD, PhD, FACP, Medical Director at Headlands Research and Principal Investigator at Headlands Research Brownsville, is a co-author on a publication exploring the co-agonism of the GPR40 and GPR119 nutrient receptors.

The study, published in Diabetes, Obesity and Metabolism, found that co-administration of K-757 and K-833 led to significant increases in satiety hormones and reductions in both weight and blood pressure—highlighting promising potential beyond glucose control.

Read more about the findings: https://headlandsresearch.com/news/combined-agonism-of-nutrient-receptors-gpr40-and-gpr119-with-k-757-and-k-833/

28/10/2025

Headlands Research is headed to the 2025 CNS Summit! We’re excited to have Tori Wallenburg, Director of Business Development, on-site to connect with industry leaders and share how our site network advances CNS research.

If you’re attending the Summit, don’t miss the chance to meet with Tori to explore how Headlands Research can support your CNS research programs.

https://headlandsresearch.com/events/cns-summit-2025/

24/10/2025

Congratulations to Dr. Timothy Bailey, President at Headlands Research – AMCR Institute, for his collaboration on a phase 3a study of CagriSema (cagrilintide + semaglutide). The study, published in the New England Journal of Medicine, showed that once-weekly treatment led to significant weight loss and improved glycemic control in adults with type 2 diabetes.

Read more: https://headlandsresearch.com/news/cagrisema-cagrilintide-semaglutide-in-adults-with-overweight-or-obesity-and-type-2-diabetes/

23/10/2025

Will we see you in Atlanta for ObesityWeek 2025? Schedule a time to chat with one of our experts at the show to learn how our network of clinical trial sites can help you achieve large-volume recruitment and retention of diverse and priority disease populations for your obesity research.

Meet our attendees:

• Christopher Romero, Medical Director for Headlands Research and Principal Investigator (PI) at Headlands Research Brownsville
• Lawrence Sher, Medical Director at PRA, a Headlands Research site
• Jason Agran, Principal Investigator at CRA, a Headlands Research site
• David Halpert, Principal Investigator at JEM Research Institute, a Headlands Research site
• Ryan Cady, Director of Cardiometabolic and Pain Strategy
• McKenzie Lang, Director of Business Development at Headlands Research

https://headlandsresearch.com/events/obesityweek-2025/

22/10/2025

October is Respiratory Syncytial Virus (RSV) Awareness Month. RSV is a common respiratory virus that can lead to serious illness in infants, older adults, and those with weakened immune systems. At Headlands Research, we’re committed to advancing clinical research that helps improve prevention and treatment options for RSV and other respiratory conditions.

By raising awareness and supporting research, we can make a difference for the most vulnerable populations.

Address

Website

http://www.headlandsresearch.com/

Alerts

Be the first to know and let us send you an email when Headlands Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City: